Alzheimer's drug trial halted: simufilam shows no benefit
Disease control
Terminated
This study tested a drug called simufilam in people with mild-to-moderate Alzheimer's disease. The goal was to see if it could slow down memory loss and help with daily activities. About 1,125 participants took either a placebo or one of two doses of simufilam twice a day for 76 …
Phase: PHASE3 • Sponsor: Cassava Sciences, Inc. • Aim: Disease control
Last updated May 18, 2026 12:04 UTC